{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:58:09Z","timestamp":1761947889573},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1097\/spc.0b013e328349731c","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T21:45:52Z","timestamp":1371159952000},"page":"258-264","source":"Crossref","is-referenced-by-count":24,"title":["Denosumab"],"prefix":"10.1097","volume":"5","author":[{"given":"Allan","family":"Lipton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-12-20211004","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity.","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R3-12-20211004","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2008.05.044","article-title":"Osteotropic cancers: from primary tumor to bone.","volume":"273","author":"Buijs","year":"2009","journal-title":"Cancer Lett"},{"key":"R4-12-20211004","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2009.0080","article-title":"The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.","volume":"7","author":"Lipton","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"R5-12-20211004","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.critrevonc.2005.03.011","article-title":"Management of bone metastases in cancer: a review.","volume":"56","author":"Selvaggi","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"R6-12-20211004","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ctrv.2007.09.002","article-title":"RANK ligand as a therapeutic target for bone metastases and multiple myeloma.","volume":"34","author":"Roodman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"R7-12-20211004","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1083\/jcb.145.3.527","article-title":"The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.","volume":"145","author":"Burgess","year":"1999","journal-title":"J Cell Biol"},{"key":"R8-12-20211004","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-9440(10)64556-7","article-title":"Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.","volume":"157","author":"Lacey","year":"2000","journal-title":"Am J Pathol"},{"key":"R9-12-20211004","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"R10-12-20211004","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1210\/endo.139.3.5837","article-title":"Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPGOCIF inhibits osteoclastogenesis in vitro.","volume":"139","author":"Yasuda","year":"1998","journal-title":"Endocrinology"},{"key":"R11-12-20211004","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","article-title":"RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.","volume":"97","author":"Li","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-12-20211004","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/pros.10349","article-title":"Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions.","volume":"58","author":"Yonou","year":"2004","journal-title":"Prostate"},{"key":"R14-12-20211004","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1073\/pnas.84.7.2024","article-title":"Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones.","volume":"84","author":"Pfeilschifter","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-12-20211004","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1010015309973","article-title":"Growth regulatory factors and bone.","volume":"2","author":"Mundy","year":"2001","journal-title":"Rev Endocr Metab Disord"},{"key":"R16-12-20211004","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/pros.20678","article-title":"RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.","volume":"68","author":"Armstrong","year":"2008","journal-title":"Prostate"},{"key":"R17-12-20211004","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bone.2008.10.047","article-title":"Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.","volume":"44","author":"Buijs","year":"2009","journal-title":"Bone"},{"key":"R18-12-20211004","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10585-007-9127-1","article-title":"Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.","volume":"25","author":"Canon","year":"2008","journal-title":"Clin Exp Metastasis"},{"key":"R19-12-20211004","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1359\/jbmr.060706","article-title":"Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration.","volume":"21","author":"Feeley","year":"2006","journal-title":"J Bone Miner Res"},{"key":"R20-12-20211004","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCEosteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R21-12-20211004","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bone.2006.09.016","article-title":"Inhibition of bone resorption, rather than direct cytotoxicity, mediates the antitumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.","volume":"40","author":"Zheng","year":"2007","journal-title":"Bone"},{"key":"R22-12-20211004","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.bone.2010.03.001","article-title":"Inhibition of RANKL increases the antitumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis.","volume":"46","author":"Canon","year":"2010","journal-title":"Bone"},{"key":"R23-12-20211004","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4161\/cbt.9.7.11266","article-title":"Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2LTRAILdulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.","volume":"9","author":"Holland","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"R24-12-20211004","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1158\/1535-7163.MCT-08-0046","article-title":"RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.","volume":"7","author":"Miller","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"R25-12-20211004","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature09495","article-title":"RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.","volume":"468","author":"Gonzalez-Suarez","year":"2010","journal-title":"Nature"},{"key":"R26-12-20211004","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.","volume":"468","author":"Schramek","year":"2010","journal-title":"Nature"},{"key":"R27-12-20211004","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature09707","article-title":"Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.","volume":"470","author":"Tan","year":"2011","journal-title":"Nature"},{"key":"R28-12-20211004","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"R29-12-20211004","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"key":"R30-12-20211004","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"R31-12-20211004","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"R32-12-20211004","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"R33-12-20211004","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update.","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"R34-12-20211004","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates.","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"R35-12-20211004","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1470-2045(10)70170-4","article-title":"Safety of denosumab in giant-cell tumor of bone.","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"},{"key":"R37-12-20211004","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","article-title":"Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with antiangiogenic agents.","volume":"27","author":"Aragon-Ching","year":"2009","journal-title":"Cancer Invest"},{"key":"R38-12-20211004","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10549-008-0131-1","article-title":"Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues.","volume":"124","author":"Launay-Vacher","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"R39-12-20211004","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.22504","article-title":"The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.","volume":"109","author":"Oh","year":"2007","journal-title":"Cancer"},{"key":"R40-12-20211004","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0272-6386(86)80112-3","article-title":"Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity.","volume":"8","author":"Ries","year":"1986","journal-title":"Am J Kidney Dis"},{"key":"R42-12-20211004","doi-asserted-by":"crossref","first-page":"e421","DOI":"10.1200\/JCO.2010.34.1511","article-title":"Denosumab for bone metastases from breast cancer: a new therapy option Reply to M.S. Aapro.","volume":"29","author":"Stopeck","year":"2011","journal-title":"J Clin Oncol"},{"key":"R43-12-20211004","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/CCO.0b013e32832c951d","article-title":"Giant cell tumour of bone.","volume":"21","author":"Thomas","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"R44-12-20211004","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["Current Opinion in Supportive & Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201109000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T02:06:39Z","timestamp":1633313199000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201109000-00012"}},"subtitle":["benefits of RANK ligand inhibition in cancer patients"],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0b013e328349731c","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}